RAPID MILESTONE ACHIEVEMENT 2017-2018 ü Camargo retained ü Pre-IND activities 2019 – 2Q 2020 ü IND Package Submissions ü Phase 1 and 2 Trials 3Q 2020 - 2021 ü Phase 3 Trials ü NDA Prep & Submission 2022 ü Approvals ü Launches CTx-1301 Development Timeline CORPORATE OVERVIEW INVESTMENT HIGHLIGHTS The Platform • PTR™ Platform has potential to fully disrupt the oral drug delivery market • Technology applicable across multiple indications, 12+ future drugs targeted for evaluation Lead Indication • Initial focus on $15B+ ADHD market with two lead candidates, offers multiple shots on goal • Drug candidates designed to address the major unmet needs of the ADHD patients– with advantages demonstrated via two successful human trials; Phase 2 pivotal bioavailability study ongoing • Accelerated development timeline, working with approved chemical entities Funding • Raised ~$26M to date. Company will raise an additional $75 million to bring ADHD assets to approval • Current offering of preferred equity units Team • Experienced management team with proven development and commercialization expertise • Established, world class scientific advisory board with recognized thought leaders Cingulate Therapeutics is a privately-held, clinical-stage biopharmaceutical company focused on the development of new and innovative medications utilizing the Company’s disruptive, proprietary Precision Timed Release™ (PTR™) drug delivery platform that allows for the creation of a true once-daily, multi-dose tablet. The Company is currently raising up to $25 million to complete Phase II and to initiate Phase III human trials for the first of two drugs in development exclusively designed to overcome the unmet medical needs of ADHD patients, a $15 billion market. By using previously approved drugs with the PTR™ platform, Cingulate will pursue FDA approval via the 505(B)(2) pathway, with market availability and meaningful ROI in as few as 24 months. Lead Assets Driving Growth: CTx-1301 & CTx-1302 FOR ADHD NO ADHD product available today combines all unmet needs: ü Lasts the entire active-day (duration) ü Rapid onset (works fast) ü Controlled descent of drug levels to minimize or avoid crash/rebound effect ü Eliminate need for afternoon booster/recovery dose ü Preferred Access / Affordability 60% of patients use short-acting ‘booster’ dose every day! © 2020 Cingulate Therapeutics